Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 7/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846273 | 1.00 | USP30 (0.35) | USP30CHRM4CYP11B2KDM1ANR3C2 | |
| SCHEMBL4234632 | 0.88 | TP53 (0.34) | GRIN2B | |
| SCHEMBL4234636 | 0.88 | TP53 (0.34) | GRIN2B | |
| SCHEMBL4233386 | 0.85 | NOTUM (0.41) | USP30CHRM4 | |
| SCHEMBL4233382 | 0.85 | NOTUM (0.41) | USP30CHRM4 | |
| SCHEMBL2864901 | 0.84 | PDE4B (0.39) | GRIN2B | |
| SCHEMBL2864897 | 0.84 | PDE4B (0.39) | GRIN2B | |
| SCHEMBL2867029 | 0.83 | DPP4 (0.38) | CHRM4 | |
| SCHEMBL2867031 | 0.83 | DPP4 (0.38) | CHRM4 | |
| SCHEMBL4235120 | 0.82 | NOTUM (0.37) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | USP30 3454/4885CHRM4 15/4885CYP11B2 4047/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | USP30 3738/4885CHRM4 13/4885CYP11B2 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.